Clinical trials in an Ebola outbreak seek to find an evidence-based cure.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Innovating health prevention models in detecting infectious disease outbreaks through social media data: an umbrella review of the evidence.Frontiers in public health · 2024
   Pooled it
2. Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review.Pharmaceutics · 2026
   Review
3. Sentiment analysis and its applications in fighting COVID-19 and infectious diseases: A systematic review.Expert systems with applications · 2021
   Review
4. Understanding COVID-19: From Origin to Potential Therapeutics.International journal of environmental research and public health · 2020
   Review

Corrections and comments

• Comment on
  Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease:  plasma concentrations exceed target levels, with drug accumulation in the most severe patients.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as